Newsletter
Stoke Therapeutics & Acadia Pharmaceuticals are working on SYNGAP1

SYNGAP10

Stoke Therapeutics & Acadia Pharmaceuticals are working on SYNGAP1

January 14, 2022

Stoke Therapeutics & Acadia Pharmaceuticals are working on SYNGAP1

BIG NEWS! https://www.businesswire.com/news/home/20220110005334/en/

FIVE KEY LINKS

– Dr. Kaye’s presentation – Listen to it again and again https://investor.stoketherapeutics.com/events/event-details/40th-annual-jp-morgan-healthcare-conference

– AES 2018 Poster https://www.stoketherapeutics.com/wp-content/uploads/Stoke-Poster-Dec-1.pdf

– STOKE Patent https://patents.google.com/patent/WO2017106377A1/en

– #OneYearSooner – How we can make clinical trials happen faster https://www.syngapresearchfund.org/post/oneyearsooner

– Sign up for Ciitizen – www.Ciitizen.com/SYNGAP1

SPREAD THE WORD

Twitter.com/cureSYNGAP1/status/1480546972645793794?s=20

Linkedin.com/feed/update/urn:li:activity:6886314132866506753

Facebook.com/cureSYNGAP1/posts/946801809535615

WHO IS WHO AT STOKE

https://www.cshl.edu/research/faculty-staff/adrian-r-krainer/ PhD Harvard 1986

https://www.linkedin.com/in/huwnash/ PhD Harvard 1997, EIR ATP since 2014

https://www.oligotherapeutics.org/officers/isabel-aznarez-ph-d/ PhD Toronto 2006

https://www.linkedin.com/in/barryticho/ MD PhD Chicago

https://www.linkedin.com/in/edward-kaye-0a46a710/ MD Loyola Chicago

COMPANIES

Stoke https://www.stoketherapeutics.com/ $ACAD

Acadia https://www.acadia-pharm.com/ $STOK

OTHER GREAT LINKS

DSF on the Monarch https://www.dravetfoundation.org/wp-content/uploads/2020/04/Stoke-Community-FAQ-April-2020.pdf 

It starts with Spinraza https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza%C2%AE-%E2%80%93-Spinal-Muscular aka https://en.wikipedia.org/wiki/Nusinersen 

Grant made in 2003, Phase 1 in 2011 (dec) FDA approval in 2016 (Dec) https://www.curesma.org/fda-approves-spinraza-for-sma/ 

From: https://www.bizjournals.com/boston/news/2018/01/04/ex-sarepta-ceo-takes-helm-of-genetic-disease.html

Stoke Origins: https://endpts.com/gene-therapy-startup-stoke-therapeutics-secures-another-90m-in-series-b-funding/ $40M from ATP in 2018. https://www.appletreepartners.com/portfolio#stoke-therapeutics 

IPO June 2019 $163M/ https://www.spglobal.com/marketintelligence/en/news-insights/trending/OTV6RnpzTCGYyRs_gx1m7A2 

REMEMBER

Raise funds at https://syngap.fund/give 

Sign up for this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a 

Episode 43 of #Syngap10 – January 14, 2022  

#StokedAboutStoke #ASO #SYNGAP1 #AcadiaPharma #StokeTx

#F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics

Send in a voice message: https://podcasters.spotify.com/pod/show/syngap10/message

ADVERTISEMENT
ADVERTISEMENT

You may also like

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Silver Sponsors

Bronze Sponsors

Event and Media Partners

Buffer LinkedIn WhatsApp